Abstract
Osteoporotic fractures are potential long-term complications of bone marrow transplantation (BMT). We previously reported that bone mineral density (BMD) of patients undergoing allogeneic BMT decreased by 6% to 9% during the first 6 months after BMT and that bone turnover rate was still increased 1 year after BMT. BMT patients do not need lifelong immunosuppressive treatment, which should offer favorable circumstances for the recovery of BMD. Thus, 27 (14 women, 13 men) of 29 long-term survivors of our previous study were invited to a follow-up study at a median of 75 months after BMT. From 12 months after BMT the BMD of the lumbar spine had increased by 2.4% (P = 0.002). The respective changes in femoral sites were +4.1% in the femoral neck (P = 0.087), 4.0% in the trochanter (P = 0.095), +4.7% in Ward's triangle (P = 0.072) and +1.4% in the total hip (P = 0.23). The markers of bone formation, serum osteocalcin and type I procollagen aminoterminal propeptide (PINP) had returned to control levels, but out of the markers of bone resorption the mean level of serum type I carboxyterminal telopeptide (ICTP) was 41% higher (P = 0.0001) and that of urinary type I collagen N-terminal telopeptide/creatinine (NTx) 41% lower (P = 0.0002) in patients than in controls. The mean serum 25-hydroxyvitamin D [25(OH)D] was 33% lower in patients (P = 0.0002), most of whom had hypovitaminosis D [serum 25(OH)D ⩽37 nmol/l]. Except for two, males had serum testosterone level lower than before BMT and four men had hypogonadism. In conclusion, in long-term survivors of allogeneic BMT BMD recovers and bone turnover state normalizes as compared to the situation 1 year after BMT. More attention should be paid to the vitamin D status of all recipients and to possible hypogonadism of male patients.
Bone Marrow Transplantation (2002) 29, 33–39. doi:10.1038/sj.bmt.1703317
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Katz IA, Epstein S . Perspectives. Post-transplantation bone disease J Bone Miner Res 1992 7: 123 126
Välimäki MJ, Kinnunen K, Volin L et al. Prospective study of bone loss and turnover after allogeneic bone marrow transplantation: effect of calcium supplementation with or without calcitonin Bone Marrow Transplant 1999 23: 355 361
Ebeling PR, Thomas DM, Erbas B et al. Mechanisms of bone loss following allogeneic and autologous hemopoietic stem cell transplantation J Bone Miner Res 1999 14: 342 350
Kanis JA, Melton LJ, Christiansen C et al. Perspective. The diagnosis of osteoporosis J Bone Miner Res 1994 9: 1137 1141
Schulte C, Beelen DW, Schaefer UW, Mann K . Bone loss in long-term survivors after transplantation of hematopoietic stem cells: a prospective study Osteoporos Int 2000 11: 344 353
Epstein S . Post-transplantation bone disease: the role of immunosuppressive agents and the skeleton J Bone Miner Res 1996 11: 1 7
Kellholz U, Max R, Schelbenbogen C et al. Endocrine function and bone metabolism 5 years after autologous bone marrow/blood-derived progenitor cell transplantation Cancer 1997 79: 1617 1622
Garnero P, Borel O, Byrjalsen I et al. The collagenolytic activity of cathepsin K is unique among mammalian proteinases J Biol Chem 1998 273: 32347 32352
Atley LM, Mort JS, Lalumiere M, Eyre DR . Proteolysis of human bone collagen by cathepsin K: characterization of the cleavage sites generating the cross-linked N-telopeptide neoepitope Bone 2000 26: 241 247
Sassi M-L, Eriksen H, Risteli L et al. Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K Bone 2000 26: 367 373
Cummings SR, Black DM, Thompson DE et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures – results from the fracture intervention trial JAMA 1998 280: 2077 2082
Pols HAP, Felsenberg D, Hanley DA et al. Multinational, placebo-controlled, randomised trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT-study Osteoporos Int 1999 9: 461 468
Adachi JD, Roux C, Pitt PI et al. A pooled data analysis on the use of intermittent etidronate therapy to prevention and treatment of corticosteroid bone loss J Rheumatol 2000 27: 2424 2431
Reid DM, Hughes RA, Laan RF et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomised trial. European corticosteroid-induced osteoporosis treatment study J Bone Miner Res 2000 15: 1006 1013
Body JJ, Bartl R, Burckhardt P et al. Current use of bisphosphonates in oncology J Clin Oncol 1998 16: 3890 3899
Shane E, Rodino MA, McMahon DJ et al. Prevention of bone loss after heart transplantation with antiresorptive therapy: a pilot study J Heart Lung Transplant 1998 17: 1089 1096
Christgau S, Bitsch-Jensen O, Hanover Bjarnason N et al. Serum crossLaps for monitoring the response in individuals undergoing antiresorptive therapy Bone 2000 26: 505 511
Garnero P, Shih WJ, Gineyts E et al. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment J Clin Endocrinol Metab 1994 79: 1693 1700
Teronen O, Heikkilä P, Konttinen YT et al. MMP inhibition and downregulation by bisphosphonates Ann NY Acad Sci 1999 878: 453 465
Thomas MK, Lloyd-Jones DM, Thandhani RI et al. Hypovitaminosis D in medical patients New Engl J Med 1998 338: 777 783
Kauppinen-Mäkelin R, Tähtelä R, Löyttyniemi E et al. A high prevalence of hypovitaminosis D in Finnish medical in- and outpatients J Intern Med 2001 249: 559 563
Kauppila M, Viikari J, Irjala K et al. The hypothalamus–pituitary–gonad axis and testicular function in male patients after treatment for haematological malignancies J Intern Med 1998 244: 411 416
Rodino MA, Shane E . Osteoporosis after organ transplantation Am J Med 1998 104: 459 469
Snyder PJ, Peachey H, Berlin JA et al. Effects of testosterone replacement in hypogonadal men J Clin Endocrinol Metab 2000 85: 2670 2677
Acknowledgements
We are indebted to Ritva Keskimäki for excellent technical support. The study was supported by a grant from the Erityisvaltionosuus (Grant TYH-9321).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kananen, K., Volin, L., Tähtelä, R. et al. Recovery of bone mass and normalization of bone turnover in long-term survivors of allogeneic bone marrow transplantation. Bone Marrow Transplant 29, 33–39 (2002). https://doi.org/10.1038/sj.bmt.1703317
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703317
Keywords
This article is cited by
-
Prevention and treatment of bone loss and fractures in patients undergoing a hematopoietic stem cell transplant: a systematic review and meta-analysis
Bone Marrow Transplantation (2017)
-
Bone mineral deficits in recipients of hematopoietic cell transplantation: the impact of young age at transplant
Bone Marrow Transplantation (2014)
-
Decreased bone mineral density in young adults treated with SCT in childhood: the role of 25-hydroxyvitamin D
Bone Marrow Transplantation (2012)
-
Bone mass and microarchitecture of irradiated and bone marrow-transplanted mice: influences of the donor strain
Osteoporosis International (2009)
-
High prevalence of early-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy
Bone Marrow Transplantation (2008)